In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...